VEGF receptor inhibition as a model of pulmonary hypertension in mice

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 10, 2011, Pages 1103-1105

  Weissmann, Norbert ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MONOCROTALINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEMAXANIB; SEROTONIN; SMAD PROTEIN; VASCULOTROPIN RECEPTOR;

CELL PROLIFERATION; DISEASE COURSE; DISEASE MODEL; EDITORIAL; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROBLAST; HEART HYPERTROPHY; HEART OUTPUT; HEART RIGHT VENTRICLE; HISTOPATHOLOGY; HUMAN; HYPOXIA; IDIOPATHIC DISEASE; LUNG ALVEOLUS CELL; LUNG RESECTION; LUNG VASCULAR RESISTANCE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHISTOSOMIASIS; SMOOTH MUSCLE FIBER; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HYPERTENSION, PULMONARY; MALE;

EID: 81455150156     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201109-1662ED     Document Type: Editorial

References (20)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349.
2. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007;28:23-42. (vii.). (Pubitemid 46335935)
3. Haddad F, Ashley E, Michelakis ED. New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Curr Opin Cardiol 2010;25:131-140.
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S. (Pubitemid 38759712)
5. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.
6. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
7. Dupuis J, Weissmann N. Animal models of pulmonary hypertension. In Yuan JX, Garcia JGN, West JB, Hales CA, Rich S, Archer SL, editors. Textbook of pulmonary vascular disease. New York: Springer US; 2011. pp. 453-458.
8. Pak O, Janssen W, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT, Weissmann N. Animal models of pulmonary hypertension: role in translational research. Drug Discov Today Dis Models 2010;7:89-97.
9. Stenmark KR, Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med 2010;11:S85-S90.
10. Crosby A, Jones FM, Southwood M, Stewart S, Schermuly R, Butrous G, Dunne DW, Morrell NW. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010;181:279-288.
11. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc MG, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438. (Pubitemid 32141434)
12. Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 2001;53:1629-1636. (Pubitemid 34044251)
13. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747-2754.
14. Kwapiszewska G, Wygrecka M, Marsh LM, Schmitt S, Trosser R, Wilhelm J, Helmus K, Eul B, Zakrzewicz A, Ghofrani HA, et al. Fhl-1, a new key protein in pulmonary hypertension. Circulation 2008;118:1183-1194.
15. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008;33:278-291. (Pubitemid 351629535)
16. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182.
17. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-1319.
18. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, Abman SH. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004;287:L344-L351. (Pubitemid 38943916)
19. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S20-S31.
20. Zhong XS, Zheng JZ, Reed E, Jiang BH. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 2004;324:471-480. (Pubitemid 39345542)